sanofi

Sanofi is to acquire all of the outstanding shares of Principia Biopharma Inc. (NASDAQ: PRNB), a South San Francisco, CA-based late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis).